Traders should monitor the March 12 earnings call for potential updates on cash runway, clinical progress, or funding developments, which could impact the stock given Vaxart's clinical-stage status and history of dilution risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $0.7600entry
- T+1 · 9mo ago −5.26%α −4.69% · $0.7200
- T+5 · 8mo ago +1.32%α +2.65% · $0.7700
- T+20 · 8mo ago −17.11%α −12.69% · $0.6300
- T+60 · 6mo ago −13.16%α −23.25% · $0.6600
Price Chart
How similar events traded
Executive Summary
Vaxart, Inc. announced upcoming webcast events to discuss its full-year 2025 financial results and provide a stockholder update. The earnings call is scheduled for March 12, 2026, after market close, followed by a stockholder fireside chat on March 13, 2026. No financial results or material updates were released in this announcement.
Key Facts
- Vaxart will report full-year 2025 financial results on March 12, 2026, after market close.
- A conference call and webcast will be held the same day at 4:30 p.m. ET.
- A stockholder fireside chat is scheduled for March 13, 2026, at 4:30 p.m. ET.
- No financial data or operational updates were disclosed in this press release.
- Replays of both events will be available on the company's website.
Financial Impact
No financial impact from this announcement; actual results to be disclosed on March 12.
Risk Factors
- High volatility expected around earnings announcement due to lack of transparency ahead of the call.
- Potential for dilutive financing or extended cash runway concerns given Vaxart's pre-revenue biotech profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248893 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers